Predictive value of serum VEGF, IL‑1 and TNF‑α in the treatment of thromboangiitis obliterans by revascularization

Abstract

Effect of revascularization in the treatment of thromboangiitis obliterans (TAO) and the predictive value of serum vascular endothelial growth factor (VEGF), interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) of risk factors of amputation were investigated. From April 2012 to August 2015, a total of 117 patients with TAO admitted to the First Hospital of Lanzhou University were selected. Patients treated with revascularization combined with prostaglandin sodium and cilostazol were enrolled in group A (67 patients), and patients treated with sodium and cilostazol were enrolled in group B (50 patients). The clinical efficacy was evaluated by calculating the intermittent claudication distance and the ankle brachial index (ABI) of patients. The occurrence probability of nausea and vomiting, skin pruritus, abdominal pain, coagulation abnormalities and amputation were recorded. The concentration of serum VEGF, IL-1 and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA). After treatment, the intermittent claudication distance, ABI and efficiency of group A was markedly higher than that of group B (P<0.05). After treatment, serum VEGF concentration in group A was clearly higher than that in group B (P<0.05), and IL-1 and TNF-α levels were much lower than those in group B (P<0.05). The amputation rate in group A was significantly lower than that in group B (P<0.05). Patients with amputation in both groups were enrolled in the study group (24 cases), and those without amputation were included in the control group (93 cases). The serum VEGF concentration in the study group before treatment was significantly lower than that in the control group (P<0.05), while IL-1 and TNF-α levels were significantly higher than those of the control group (P<0.05). In conclusion, pretreatment serum VEGF, IL-1 and TNF-α had a positive diagnostic value for poor prognosis of patients with amputation, and low concentration of VEGF and higher concentration of IL-1 and TNF-α are the risk factors for amputations in patients with TAO.

A scope systematic review to clarify immune response to tobacco in Buerger

“…All articles were patient-based and 7 articles were conducted in Iran, 4 in China and one in Korea. Systematic reviews and metaanalyses were not available, all clinical trials were not ethically prohibited, and randomized trials were assessed based on Consort checklists (11,(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28).…”

“…o TNF reduce reperfusion in TOA by tobacco We concepted that cytokine induced TOA, one of the most effective in ammatory parameters in Buerger is TNF. It can be said that the hottest discussion in our available studies has been TNF-α, along with IL-6 and IL-1 (23,34). The roles of TNF include involvement in in ammation, muscle weakness, and pain in TOA.…”

Induced pluripotent stem cells can improve thrombolytic effect of low-dose rt-PA after acute carotid thrombosis in rat

“…Pro-angiogenic therapy using VEGF may be useful in ischemic diseases such as stroke, myocardial ischemia and coronary artery disease [ 49 ]. VEGF and IL‑1 act inversely as the risk factors in the treatment of thromboangiitis obliterans by revascularization [ 50 ], and IL-1 may induce VEGF production in chondrocytes through distinct signaling pathways [ 51 ]. VEGF has the ability to increase ICAM-1 expression in the retinal vasculature and ICAM-1 can mediate VEGF-induced vascular permeability and nonperfusion [ 52 ].…”

Vascular endothelial growth factor is an effective biomarker for vascular dementia, not for Alzheimer's disease: A meta‐analysis

“…5 Vascular endothelial growth factor (VEGF), a natural growth factor encoded by the VEGFA gene, participates in physiological processes relating to blood vessels and metabolism, including blood vessel growth, endothelial cell destruction, oxygen and glucose delivery, and blood vessel permeability. 6,7 Considering vascular factors and the role of VEGF in AD and VaD, numerous studies have evaluated the diagnostic capability of VEGF for different types of dementia in humans. Some studies have found significant differences in blood or cerebrospinal fluid (CSF) levels between AD or VaD subjects and cognitively normal (CN) subjects, suggesting the possibility of diagnosing these two forms of dementia.…”

“…Vascular endothelial growth factor (VEGF), a natural growth factor encoded by the VEGFA gene, participates in physiological processes relating to blood vessels and metabolism, including blood vessel growth, endothelial cell destruction, oxygen and glucose delivery, and blood vessel permeability 6,7 . Considering vascular factors and the role of VEGF in AD and VaD, numerous studies have evaluated the diagnostic capability of VEGF for different types of dementia in humans.…”